Furong Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Furong Qiu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Jingyi Jin
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
4 shared publicationsBin Zou
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
3 shared publicationsFengling Li
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
3 shared publicationsFengyi Weng
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
3 shared publicationsShuang Zhang
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
3 shared publicationsDongming Yan
Laboratory of Clinical Pharmacokinetics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201213, China
2 shared publications
Latest Publications
- 10 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 362, 121356
Gancao decoction ameliorated senecionine-induced Hepatic Sinusoidal Obstruction Syndrome in mice by inhibiting NET formation and senecionine bioactivation in liver
- 10 February 2026
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 362, 121356
Gancao decoction ameliorated senecionine-induced Hepatic Sinusoidal Obstruction Syndrome in mice by inhibiting NET formation and senecionine bioactivation in liver
- 23 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1015, 178595
Glycyrrhetinic acid ameliorates cholestatic liver injury by inhibiting acHMGB1/TLR2-mediated crosstalk between hepatocytes and macrophages
- 23 January 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1015, 178595
Glycyrrhetinic acid ameliorates cholestatic liver injury by inhibiting acHMGB1/TLR2-mediated crosstalk between hepatocytes and macrophages
- 26 April 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (6) , e70094
Comparative Study of Pharmacokinetics and Renal Exposure of Salvianolic Acid B and Its Metabolite Danshensu in Normal and Renal Fibrosis Mice
Salvianolic acid B (SAB), a water‐soluble compound in Salvia miltiorrhiza (Danshen), has been widely used in the treatment of renal fibrosis. This study aimed to investigate the pharmacokinetics of SAB and its active metabolite danshensu (DSS) after intraperitoneal injection of Salvia miltiorrhiza depside salt for injection (SDSI) or SAB in normal and unilateral ureteric obstruction (UUO) mice. An LC‐MS/MS method was developed to simultaneously determine the SAB and DSS in biological samples. The validation results showed that the linearity, accuracy and precision, matrix effects and recovery, and stability satisfied the FDA bioanalysis guidelines. Pharmacokinetic study showed that plasma and renal exposure of SAB in mice administered SAB were higher than that in mice administered SDSI in the sham group, while those of DSS were lower. Compared with the sham group, the AUC0‐t of SAB in obstructed kidneys (OKs) and non‐obstructed kidneys (NOKs) of the UUO group decreased by 71.14% and 54.63%, respectively. The AUC0‐t of DSS in the OKs and NOKs of the UUO group increased by 60.8% and 177.79%, respectively, compared with the sham group. Developed method was successfully applied to the bioanalysis of SAB and DSS. Our study provides pharmacokinetic support for the rational clinical application of SAB.
- 26 April 2025
- Published by Wiley in Biomedical Chromatography
- Vol. 39 (6) , e70094
Comparative Study of Pharmacokinetics and Renal Exposure of Salvianolic Acid B and Its Metabolite Danshensu in Normal and Renal Fibrosis Mice
Salvianolic acid B (SAB), a water‐soluble compound in Salvia miltiorrhiza (Danshen), has been widely used in the treatment of renal fibrosis. This study aimed to investigate the pharmacokinetics of SAB and its active metabolite danshensu (DSS) after intraperitoneal injection of Salvia miltiorrhiza depside salt for injection (SDSI) or SAB in normal and unilateral ureteric obstruction (UUO) mice. An LC‐MS/MS method was developed to simultaneously determine the SAB and DSS in biological samples. The validation results showed that the linearity, accuracy and precision, matrix effects and recovery, and stability satisfied the FDA bioanalysis guidelines. Pharmacokinetic study showed that plasma and renal exposure of SAB in mice administered SAB were higher than that in mice administered SDSI in the sham group, while those of DSS were lower. Compared with the sham group, the AUC0‐t of SAB in obstructed kidneys (OKs) and non‐obstructed kidneys (NOKs) of the UUO group decreased by 71.14% and 54.63%, respectively. The AUC0‐t of DSS in the OKs and NOKs of the UUO group increased by 60.8% and 177.79%, respectively, compared with the sham group. Developed method was successfully applied to the bioanalysis of SAB and DSS. Our study provides pharmacokinetic support for the rational clinical application of SAB.
- 6 March 2024
- Published by Wiley in Journal of Applied Toxicology
- Vol. 44 (7) , 978-989
Physiologically based pharmacokinetic modeling for confirming the role of CYP3A1/2 and P‐glycoprotein in detoxification mechanism between glycyrrhizic acid and aconitine in rats
Fuzi, an effective common herb, is often combined with Gancao to treat disease in clinical practice with enhancing its efficacy and alleviating its toxicity. The major toxic and bioactive compounds in Fuzi and Gancao are aconitine (AC) and glycyrrhizic acid (GL), respectively. This study aims to elucidate detoxification mechanism between AC and GL from pharmacokinetic perspective using physiologically based pharmacokinetic (PBPK) model. In vitro experiments exhibited that AC was mainly metabolized by CYP3A1/2 in rat liver microsomes and transported by P‐glycoprotein (P‐gp) in Caco‐2 cells. Kinetics assays showed that the Km and Vmax of AC towards CYP3A1/2 were 2.38 μM and 57.3 pmol/min/mg, respectively, whereas that of AC towards P‐gp was 11.26 μM and 147.1 pmol/min/mg, respectively. GL markedly induced the mRNA expressions of CYP3A1/2 and MDR1a/b in rat primary hepatocytes. In vivo studies suggested that the intragastric and intravenous administration of GL significantly reduced systemic exposure of AC by 27% and 33%, respectively. Drug–drug interaction (DDI) model of PBPK predicted that co‐administration of GL would decrease the exposure of AC by 39% and 45% in intragastric and intravenous dosing group, respectively. The consistency between predicted data and observed data confirmed that the upregulation of CYP3A1/2 and P‐gp was the crucial detoxification mechanism between AC and GL. Thus, this study provides a demonstration for elucidating the compatibility mechanisms of herbal formula using PBPK modeling and gives support for the clinical co‐medication of Fuzi and Gancao.
- 6 March 2024
- Published by Wiley in Journal of Applied Toxicology
- Vol. 44 (7) , 978-989
Physiologically based pharmacokinetic modeling for confirming the role of CYP3A1/2 and P‐glycoprotein in detoxification mechanism between glycyrrhizic acid and aconitine in rats
Fuzi, an effective common herb, is often combined with Gancao to treat disease in clinical practice with enhancing its efficacy and alleviating its toxicity. The major toxic and bioactive compounds in Fuzi and Gancao are aconitine (AC) and glycyrrhizic acid (GL), respectively. This study aims to elucidate detoxification mechanism between AC and GL from pharmacokinetic perspective using physiologically based pharmacokinetic (PBPK) model. In vitro experiments exhibited that AC was mainly metabolized by CYP3A1/2 in rat liver microsomes and transported by P‐glycoprotein (P‐gp) in Caco‐2 cells. Kinetics assays showed that the Km and Vmax of AC towards CYP3A1/2 were 2.38 μM and 57.3 pmol/min/mg, respectively, whereas that of AC towards P‐gp was 11.26 μM and 147.1 pmol/min/mg, respectively. GL markedly induced the mRNA expressions of CYP3A1/2 and MDR1a/b in rat primary hepatocytes. In vivo studies suggested that the intragastric and intravenous administration of GL significantly reduced systemic exposure of AC by 27% and 33%, respectively. Drug–drug interaction (DDI) model of PBPK predicted that co‐administration of GL would decrease the exposure of AC by 39% and 45% in intragastric and intravenous dosing group, respectively. The consistency between predicted data and observed data confirmed that the upregulation of CYP3A1/2 and P‐gp was the crucial detoxification mechanism between AC and GL. Thus, this study provides a demonstration for elucidating the compatibility mechanisms of herbal formula using PBPK modeling and gives support for the clinical co‐medication of Fuzi and Gancao.